MTMohit Tyagi

Mohit Tyagi

*This is an algorithmically generated author record based on publicly available information.

Mohit Tyagi has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    What Is in a Structure? Cell Permeability and Solubility of Series of Macrocycles and Linear Matched Pairs

    by Mohit Tyagi, Vasanthanathan Poongavanam, Stefanie Zich, Marika Lindhagen, Ioannis Asproudis, Okky Dwichandra Putra, Jie Yang, Zackary J. R. Ashworth, Anna Guadagni, Luca J. Hagemeyer, et al.

    Macrocycles are a highly interesting modality to modulate difficult-to-drug targets, but often reside in chemical space where obtaining sufficient cell permeability and solubility is challenging. We have determined permeability across Caco-2 cells, aqueous solubility and log D for four series of semipeptidic macrocycles and one series of linear matched molecular pairs. By using X-ray crystallography, NMR spectroscopy, and computational chemistry, unexpected permeability differences between series and matched pairs were explained by differences in conformational preferences that determine the formation of intramolecular interactions. Macrocycles that formed intramolecular NH-π interactions and hydrogen bonds were more permeable than matched pairs unable to form such interactions. The elevated permeability of linear compounds was concluded to result from their greater conformational flexibility, allowing them to shield amide bonds and expose nonpolar groups to a greater extent than their macrocyclic matched pairs. Solubility was less dependent on specific intramolecular interactions and was predominantly low at log D >2.5.

  • Open Access

    Discovery of a Series of Macrocycles as Potent Inhibitors of Leishmania Infantum

    by Federico Riu, Larissa Alena Ruppitsch, Duc Duy Vo, Richard S. Hong, Mohit Tyagi, An Matheeussen, Sarah Hendrickx, Vasanthanathan Poongavanam, Guy Caljon, Ahmad Y. Sheikh, et al.

    Macrocycles are prominent among drugs for treatment of infectious disease, with many originating from natural products. Herein we report on the discovery of a series of macrocycles structurally related to the natural product hymenocardine. Members of this series were found to inhibit the growth of Plasmodium falciparum, the parasite responsible for most malaria cases, and of four kinetoplastid parasites. Notably, macrocycles more potent than miltefosine, the only oral drug used for the treatment of the neglected tropical disease visceral leishmaniasis, were identified in a phenotypic screen of Leishmania infantum. In vitro profiling highlighted that potent inhibitors had satisfactory cell permeability with a low efflux ratio, indicating their potential for oral administration, but low solubility and metabolic stability. Analysis of predicted crystal structures suggests that optimization should focus on the reduction of pi-pi crystal packing interactions to reduce the strong crystalline interactions and improve the solubility of the most potent lead.